

**RPG LIFE SCIENCES LIMITED**

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030

(Rs. in Lakhs)

**Statement of Financial Results for the quarter and year ended 31st March 2020**

Particulars	Quarter ended			Year ended	
	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue from Operations	8,867	9,437	6,880	37,557	33,016
2 Other Income	38	4	42	73	80
<b>3 Total Income</b>	<b>8,905</b>	<b>9,441</b>	<b>6,922</b>	<b>37,630</b>	<b>33,096</b>
<b>4 Expenses</b>					
(a) Cost of Materials Consumed	1,817	2,273	953	7,513	5,117
(b) Purchases of Stock-in-Trade	927	1,849	1,212	5,861	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	308	(932)	159	(598)	1,371
(d) Employee Benefits Expense	2,368	2,417	1,991	9,590	8,993
(e) Finance Costs	30	36	91	175	399
(f) Depreciation and Amortisation Expense	412	416	394	1,636	1,532
(g) Other Expenses	2,197	2,341	1,910	9,276	9,663
<b>Total Expenses</b>	<b>8,059</b>	<b>8,400</b>	<b>6,710</b>	<b>33,453</b>	<b>31,591</b>
<b>5 Profit before exceptional items and tax</b>	<b>846</b>	<b>1,041</b>	<b>212</b>	<b>4,177</b>	<b>1,505</b>
6 Exceptional Items Gain/(Loss) (See Note 5)	(532)	-	-	(532)	-
<b>7 Profit before tax</b>	<b>314</b>	<b>1,041</b>	<b>212</b>	<b>3,645</b>	<b>1,505</b>
8 Income tax expenses					
a. Current Tax	62	327	18	1,010	284
b. Deferred Tax	(46)	(77)	40	(266)	140
<b>9 Profit for the period</b>	<b>298</b>	<b>791</b>	<b>154</b>	<b>2,901</b>	<b>1,081</b>
10 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	6	(10)	(23)	(24)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	2	8	7	14
<b>Other Comprehensive Income Net of Tax</b>	<b>5</b>	<b>(8)</b>	<b>(15)</b>	<b>(17)</b>	<b>(27)</b>
<b>11 Total Comprehensive Income for the period</b>	<b>303</b>	<b>783</b>	<b>139</b>	<b>2,884</b>	<b>1,054</b>
12 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
13 Other Equity				16,334	14,727
14 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):					
(a) Basic	1.80	4.78	0.93	17.54	6.54
(b) Diluted	1.80	4.78	0.93	17.54	6.54

Statement of Assets and Liabilities as at March 31, 2020

(Rs. in Lakhs)

Particulars	As at 31st March 2020	As at 31st March 2019
	<b>(Audited)</b>	
<b>ASSETS</b>		
<b><u>Non-current assets</u></b>		
Property, plant and equipment	8,372	8,251
Capital work-in-progress	728	1,012
Other intangible assets	3,917	4,513
Intangible assets under development	270	705
Financial assets		
ii . Loans	18	10
iii. Other financial assets	28	30
Deferred tax assets (Net)	460	618
Current Tax asset	190	125
Other non-current assets	112	151
<b>Total non-current assets</b>	<b>14,095</b>	<b>15,415</b>
<b><u>Current assets</u></b>		
Inventories	4,661	4,104
Financial assets		
i. Trade receivables	6,333	3,890
ii. Cash and cash equivalents	54	37
iii. Bank balances other than (ii) above	57	40
iv. Other financial assets	113	96
Other current assets	1,360	1,542
<b>Total current assets</b>	<b>12,578</b>	<b>9,709</b>
<b>Total assets</b>	<b>26,673</b>	<b>25,124</b>
<b>EQUITY AND LIABILITIES</b>		
<b><u>Equity</u></b>		
Equity share capital	1,323	1,323
<b><u>Other equity</u></b>		
Reserves and Surplus	16,334	14,727
<b>Total equity</b>	<b>17,657</b>	<b>16,050</b>
<b>LIABILITIES</b>		
<b><u>Non-current liabilities</u></b>		
Financial liabilities		
i. Borrowings	152	658
i. Other financial liabilities	333	299
Provisions	272	335
<b>Total non-current liabilities</b>	<b>757</b>	<b>1,292</b>
<b><u>Current liabilities</u></b>		
Financial liabilities		
i. Borrowings	512	2,904
ii. Trade payables		
-Total Outstanding Dues of Micro Enterprises and Small Enterprises	396	-
-Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	4,045	2,513
iii. Other financial liabilities	1,514	823
Provisions	1,276	1,033
Other current liabilities	516	509
<b>Total current liabilities</b>	<b>8,259</b>	<b>7,782</b>
<b>Total liabilities</b>	<b>9,016</b>	<b>9,074</b>
<b>Total equity and liabilities</b>	<b>26,673</b>	<b>25,124</b>

Statement of cash flows for the year ended March 31, 2020

(Rs. in Lakhs)

	Particulars	Year ended	Year ended
		31 March 2020	31 March 2019
		Audited	Audited
<b>A</b>	<b>Cash Flow from operating activities</b>		
	<b>Profit before income tax</b>	<b>3,645</b>	1,505
	Adjustments for		
	<b>Add:</b>		
	Depreciation and amortisation expenses	<b>1,636</b>	1,532
	Finance costs	<b>175</b>	399
	Loss on disposal of property, plant and equipment	<b>11</b>	6
	Unrealised exchange rate difference	<b>(80)</b>	25
	Provision for Doubtful Debts and Advances (Net)	<b>-</b>	60
	Interest received	<b>(17)</b>	(12)
	Provisions no longer required and written back	<b>(5)</b>	(2)
	Exceptional Items (Gain)/Loss	<b>532</b>	-
		<b>5,897</b>	3,513
	<b>Working capital adjustments:</b>		
	(Increase)/Decrease in trade receivables	<b>(2,353)</b>	2,860
	(Increase) in financial assets - Loans	<b>(6)</b>	(3)
	Decrease in other non-current assets	<b>-</b>	6
	(Increase) in other financial assets	<b>(17)</b>	(8)
	Decrease in other current assets	<b>182</b>	334
	(Increase)/Decrease in inventories	<b>(557)</b>	1,265
	Increase/(Decrease) in trade payables	<b>1,933</b>	(2,673)
	Increase/(Decrease) in other financial liabilities	<b>418</b>	(332)
	Increase/(Decrease) in provisions	<b>156</b>	(177)
	Increase in other current liabilities	<b>7</b>	165
	<b>Cash generated from operations</b>	<b>5,660</b>	4,950
	Income taxes paid	<b>(643)</b>	(372)
	<b>Net cash inflow from operating activities</b>	<b>5,017</b>	4,578
<b>B</b>	<b>Cash flow from investing activities:</b>		
	Acquisition of property, plant and equipment and Intangible assets	<b>(1,074)</b>	(1,968)
	Proceeds from sale of property, plant and equipment and Intangible assets	<b>4</b>	11
	Bank deposits- (repaid) / received	<b>(17)</b>	43
	Interest received	<b>17</b>	12
	<b>Net cash (outflow) from investing activities</b>	<b>(1,070)</b>	(1,902)
<b>C</b>	<b>Cash flow from financing activities</b>		
	Proceeds from long term borrowings	<b>-</b>	311
	Repayment of long term borrowings	<b>(21)</b>	(1,195)
	Repayment of short-term borrowings (net)	<b>(2,392)</b>	(888)
	Interest paid	<b>(148)</b>	(399)
	Repayment of principal portion of lease liabilities	<b>(68)</b>	-
	Interest paid on lease liabilities	<b>(24)</b>	-
	Dividend paid including dividend distribution tax thereon	<b>(1,277)</b>	(479)
	<b>Net cash (outflow) from financing activities</b>	<b>(3,930)</b>	(2,650)
	<b>Net increase in cash and cash equivalents</b>	<b>17</b>	26
	Add: Cash and cash equivalents at the beginning of the financial year	<b>37</b>	11
	<b>Cash and cash equivalents at the end of the year</b>	<b>54</b>	37
	<b>Cash Flow statement as per above comprises of the following</b>		
	Cash and cash equivalents	<b>54</b>	37
		<b>54</b>	37

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on June 05, 2020.
- 2 Figures for the quarter ended March 31, 2020 and the corresponding quarter in the previous year as reported in the financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- 3 The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- 4 Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using the modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact on the financial results.
- 5 Exceptional items for the year ended March 31, 2020 relates to write off of an intangible asset under development. The Company does not expect any future economic benefits to flow to the Company hence the cost incurred till date have been charged off during the quarter.
- 6 The Ministry of Home Affairs on March 24, 2020 notified a nation-wide lockdown in India to contain the outbreak of the COVID-19 pandemic due to which there have been several restrictions imposed by the Governments across the globe on the travel, movement of goods and transportation considering public health and safety measures. The Company is in the business of manufacturing and supplying pharmaceutical products which are categorised under essential goods and the production facilities of the Company remain operational following enhanced internal safety guidelines. The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial statements by the Board of Directors. During this period, sales of the Company's products continue and it does not expect any material financial impact at this point of time on the demand of its products, its liquidity, assets, debt servicing abilities and supply chain operations. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Company will continue to closely monitor any material changes to future economic conditions.

For RPG Life Sciences Limited

Yugal Sikri  
Managing Director  
Mumbai, June 05, 2020